A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series

被引：24
|
作者：
Vaz, RJ [1 ]
Nayeem, A [1 ]
Santone, K [1 ]
Chandrasena, G [1 ]
Gavai, AV [1 ]
机构：
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2005年 / 15卷 / 17期
关键词：
CYP2D6; 3D-QSAR; aryloxypropanolamines;
D O I：
10.1016/j.bmcl.2005.06.007
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A comparative molecular similarity index analysis (CoMSiA) has been performed for cytochrome P450 2D6 inhibition on a series of aryloxypropatiolamines to determine the factors contributing to this activity. The model is in agreement with a CYP2D6 homology model constructed on the basis of the mammalian CYP2C5 crystal structure. The energy minimized conformations were generated using the systematic search methodology in Sybyl 6.7. The model not only elucidated the relationship between structure and biological activity but, more importantly, provided useful strategies to modulate CYP2D6 affinity in the aryloxypropanolamine series. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码：3816 / 3820
页数：5
相关论文
共 50 条
  • [1] QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series.
    Gavai, AV
    Vaz, RJ
    Santone, K
    Chandrasena, G
    Nayeem, A
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U66 - U66
  • [2] QSAR studies of quinidine inhibition of CYP2D6
    Hutzler, JM
    Wienkers, LC
    DRUG METABOLISM REVIEWS, 2002, 34 : 172 - 172
  • [3] 3D-QSAR of CYP2A6 inhibitors
    Rahnasto, M.
    Wittekindt, C.
    Poso, A.
    Raunio, H.
    Juvonen, R. O.
    TOXICOLOGY LETTERS, 2005, 158 : S61 - S61
  • [4] Pharmacophoric fingerprint method (TOPP) for 3D-QSAR modeling: Application to CYP2D6 metabolic stability
    Sciabola, Simone
    Morao, Inaki
    de Groot, Marcel J.
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2007, 47 (01) : 76 - 84
  • [5] 3D-QSAR of CYP2B6 inhibitors
    Korhonen, L. E.
    Rahnasto, M.
    Wittekindt, C.
    Poso, A.
    Raunio, H.
    Juvonen, R. O.
    TOXICOLOGY LETTERS, 2005, 158 : S50 - S50
  • [6] Exposure to oral oxycodone is increased by simultaneous inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone
    Gronlund, J.
    Hagelberg, N.
    Saari, T.
    Neuvonen, P.
    Olkkola, K.
    EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2010, 27 (01) : 144 - 144
  • [7] Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone
    Gronlund, Juha
    Saari, Teijo I.
    Hagelberg, Nora M.
    Neuvonen, Pertti J.
    Olkkola, Klaus T.
    Laine, Kari
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (01) : 78 - 87
  • [8] STEREOSELECTIVE INHIBITION OF CYP2D6 BY CHLORPHENIRAMINE
    SALCEDO, JA
    YASUDA, SU
    MURPHY, MP
    WOOSLEY, RL
    FLOCKHART, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (02) : 149 - 149
  • [9] Inhibition of CYP2D6 activity by bupropion
    Kotlyar, M
    Brauer, LH
    Tracy, TS
    Hatsukami, DK
    Harris, J
    Bronars, CA
    Adson, DE
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (03) : 226 - 229
  • [10] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
12345